QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

Sponsor

Altor BioScience (Industry)

Overall Status

Terminated

CT.gov ID

NCT01670994

Collaborator

National Cancer Institute (NCI) (NIH)

Enrollment

Location

Arm

Duration (Months)

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a Phase Ib/II, open-label, multi-center and competitive enrollment study of ALT-801 in patients who have relapsed or refractory multiple myeloma.

Condition or Disease	Intervention/Treatment	Phase
Relapsed or Refractory Multiple Myeloma	Biological: ALT-801	Phase 1/Phase 2

Detailed Description

Multiple Myeloma (MM) is a plasma cell malignancy that makes up 1% of all cancers and 10% of hematologic neoplasma, and is the second most commonly diagnosed hematologic malignancy. There are an estimated 20,520 new cases of MM and 10,610 deaths due to MM in the United States. Historically, standard first-line therapy for MM consisted of combination therapy with an alkylating agent, such as melphalan and prednisone. Response rates with such combination therapy are approximately 50%, but five-year survival rates remain low at 33%. For younger patients, debulking chemotherapy followed by autologous stem cell transplant (ASCT) with melphalan is the treatment of choice to increase the potential for a sustained durable remission. However, a large percentage of patients diagnosed with MM are not suitable candidates for ASCT because of age or comorbidities. The approach to MM treatment has undergone a radical transformation over the past decade with the introduction of the proteasome inhibitor, bortezomib, and immunomodulatory drugs (ImiDs), thalidomide or lenalidomide. Despite some advances in the treatment of MM, the disease remains incurable due to the persistence of minimal residual disease. Thus, novel modalities complementing or improving current treatment options are needed.

There is ample evidence that immunomodulatory drugs are effective against myeloma. Lenalidomide and thalidomide have been shown to stimulate T cells in the presence of antigen presenting cells via costimulatory pathway. Also, modulation of NK cell function has been associated with anti-tumor activity observed in MM patients treated with lenalidomide. It has been demonstrated that NK cells exhibit potent anti-MM activity following IL-2 administration, and ex vivo IL-2-activated and intravenously administered NK cells prolong survival in MM-bearing mice. Thus further demonstrating the role and importance of NK cells in the treatment of MM. Taken together, these data suggest that the use of a potent immunotherapeutic is an attractive approach to provide durable immune responses to or even potentially curing patients with MM.

Additionally, immunotherapy is a well-established approach for treating other cancer types. One strategy that has received attention is treatment with cytokines such as IL-2 to enhance anti-tumor immunity. Unfortunately, the considerable toxicity associated with this treatment makes it difficult to achieve an effective dose at the site of the tumor and limits the population that can be treated. Thus, there is a critical need for innovative strategies that enhance the effects of IL-2, reduce its toxicity without compromising clinical benefit, provide a more convenient dosing regimen, and treat other diagnoses including MM.

Altor Bioscience Corp. has developed a tumor-targeted IL-2 fusion protein, ALT-801, comprising human recombinant IL-2 genetically linked to a TCR domain capable of binding a tumor associated human p53 peptide presented in the context of HLA-A2. Animal studies have indicated that ALT-801 could be useful in a therapeutic approach for activating immune effector cells, bringing together effector cells and tumor cells and stimulating immune cell-mediated activity. In addition, in various mouse xenograft models, this molecule increases the efficacy but lessens the side effects of high-dose rhIL-2.

Moreover, human studies indicate ALT-801 given daily for two 4-day cycles at the MTD (i.e. 0.04 mg/kg) is well tolerated, exhibits a favorable PK drug profile, exhibits immunological potency in humans, provides evidence of clinical benefit in cancer patients and a higher dosing level (0.08 mg/kg) of ALT-801 in a monotherapy treatment was associated with better clinical benefit in patients with metastatic cancer.

Also, the results of pre-clinical studies in various tumors with diverse origins and relevant MM models indicates ALT-801 is a potent immunostimulatory molecule capable increasing NK cell and CD8+ T cell numbers and percentages in myeloma tumor-bearing mice, ALT-801 in single or multidose treatment regimens exhibits potent anti-tumor activity and induced long-lasting immunologic memory against well-established myeloma cells in the immunocompetent mouse model, suggesting the potential of curative treatment for patients with MM.

Based on these findings, ALT-801 as a single-agent therapeutic may provide durable clinical benefit to patients with relapsed or relapsed and refractory MM. In this study, we will establish the tolerable dose level of ALT-801 in MM patients, and estimate the anti-tumor activity and characterize the pharmacokinetic and immunogenicity profile of ALT-801 in such patients.

Study Design

Study Type:

Interventional

Actual Enrollment :

6 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

Study Start Date :

Aug 1, 2012

Actual Primary Completion Date :

Aug 1, 2013

Actual Study Completion Date :

Sep 1, 2015

Arms and Interventions

Arm	Intervention/Treatment
Experimental: ALT-801	Biological: ALT-801 Intravenous infusion; 2 treatment cycles: on day 1, 3, 8, and 15 of each cycle Other Names: c264scTCR-IL2

Arm

Intervention/Treatment

Experimental: ALT-801

Biological: ALT-801

Intravenous infusion; 2 treatment cycles: on day 1, 3, 8, and 15 of each cycle

Other Names:

c264scTCR-IL2

Outcome Measures

Primary Outcome Measures

Safety Profile [7 weeks]
For phase Ib & II Number and severity of treatment related AEs that occur or worsen after the first dose of study treatment
Tolerability and MTD designation [7 weeks]
For phase Ib only To evaluate the tolerability and to determine the maximum tolerated dose (MTD) level.

Secondary Outcome Measures

Clinical Benefit [12 weeks]
For phase Ib and II Number of participants with an objective response, which includes, a complete response, a partial response or a stable disease
Immunogenicity and Pharmacokinetics [8 weeks]
For phase Ib and II Measures the anti-ALT-801 and IL-2 neutralizing effects Area under the plasma concentration-time curve from time zero to infinity (AUC) and the half-life of ALT-801
Tumor Typing [1 month]
For phase Ib and II To assess the relationship between tumor presentation of HLA-A*0201/p53 aa 264-272 complex and the safety, immune response and clinical benefit of study treatment
Overall and progression-free survival [3 years]
For phase Ib and II All enrolled patients will be assessed every 3 months during year 1 and then every 6 months during years 2 and 3 from the start of study treatment to determine their overall and progression-free survival
Duration of Response [up to 3 years]
All enrolled patients will be assessed every 3 months during year 1 and then every 6 months during years 2 and 3 from the start of study treatment to determine their duration of response

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

ENTRY CRITERIA:

DISEASE CHARATERISTICS:

Confirmed diagnosis of relapsed/refractory multiple myeloma after treatment with at least two different previous regimens.
Refractory disease is defined as progressive disease while on therapy or progression within 60 days of therapy.
Progressive disease is defined by a 25% increase from the lowest response value in specified tests.
Measurable disease as defined by at least one of the following:
Serum M-protein ≥ 1g/dL (for IgG, IgM) or 0.5 g/dL (for IgA)
Urine M-protein ≥ 200mg/24hours
Serum free light chains ≥ 10 mg/dL and abnormal kappa/lambda ratio

PRIOR/CONCURRENT THERAPY:

No anti-myeloma treatments within 28 days before the start of study treatment.
Must have recovered from side effects of prior treatments.

PATIENT CHARACTERISTICS:

Age

• ≥ 18 years

Performance Status

• ECOG 0, 1, or 2

Bone Marrow Reserve

Absolute neutrophil count (AGC/ANC) ≥ 1,000/uL
Platelets ≥ 30,000/uL
Hemoglobin ≥ 8g/dL

Renal Function

• Glomerular Filtration Rate (GFR) > 45mL/min/1.73m^2

Hepatic Function

Total bilirubin ≤ 2.0 X ULN
AST, ALT, ALP ≤ 3.0 X ULN, or ≤ 5.0 X ULN (if liver metastases exist)

Cardiovascular

No congestive heart failure < 6 months
No unstable angina pectoris < 6 months
No myocardial infarction < 6 months
No history of ventricular arrhythmias
No history of supraventricular arrhythmias
No NYHA Class > II CHF
Normal Transthoracic Echocardiogram (TTE) is required for patients with history of EKG abnormalities, CHF, coronary artery disease or other cardiac disease, or with a history of having received adriamycin or doxorubicin
Patients with a left ventricular ejection fraction (LVEF) of less than 50% will be excluded from study entry

Pulmonary

• Normal clinical assessment of pulmonary function

Other

Negative serum pregnancy test if female and of childbearing potential
Women who are not pregnant or nursing
Subjects, both females and males, with reproductive potential must agree to use effective contraceptive measures for the duration of the study
No known autoimmune disease other than corrected hypothyroidism
No known prior organ allograft or allogeneic transplantation
Not HIV positive
No history or evidence of uncontrollable CNS disease
No psychiatric illness/social situation
No other illness that in the opinion of the investigator would exclude the subject from participating in the study
Must provide informed consent and HIPPA authorization and agree to comply with all protocol-specified procedures and follow-up evaluations
Active systemic infection requiring parenteral antibiotic therapy.
No ongoing chronic systemic steroid therapy required.